Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8930374rdf:typepubmed:Citationlld:pubmed
pubmed-article:8930374lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C0066908lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C0009647lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C1546857lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C1556066lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C1619636lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C1514873lld:lifeskim
pubmed-article:8930374lifeskim:mentionsumls-concept:C1627358lld:lifeskim
pubmed-article:8930374pubmed:issue1-2lld:pubmed
pubmed-article:8930374pubmed:dateCreated1997-2-20lld:pubmed
pubmed-article:8930374pubmed:abstractTextThe type of opioid receptors involved in the conditioned enhancement of natural killer (NK) cell activity is identified in the present study. In our previous observations, we have demonstrated that the conditioned enhancement of NK cell activity was dependent on beta-endorphin and methionine-enkephalin, but not dynorphin. Based on the interaction of opioids with their homologous receptors, we concluded that mu- and delta-opioid receptors might be involved. To further classify the type(s) of opioid receptors involved in eliciting the conditioned NK cell activity, three opioid receptor antagonists, cyprodime hydrobromide, ICI-174864, and nor-binaltorphimine dihydrochloride, were used to block the conditioned NK cell activity in BALB/c mice. Blocking was conducted by intracisternal injection of the drugs. The results showed that the activation of mu-opioid receptors was required in the conditioned enhancement of NK cell activity, but not the delta- or kappa-type of receptors.lld:pubmed
pubmed-article:8930374pubmed:languageenglld:pubmed
pubmed-article:8930374pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:citationSubsetIMlld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8930374pubmed:statusMEDLINElld:pubmed
pubmed-article:8930374pubmed:monthOctlld:pubmed
pubmed-article:8930374pubmed:issn0006-8993lld:pubmed
pubmed-article:8930374pubmed:authorpubmed-author:HiramotoR NRNlld:pubmed
pubmed-article:8930374pubmed:authorpubmed-author:GhantaV KVKlld:pubmed
pubmed-article:8930374pubmed:authorpubmed-author:ChenS FSFlld:pubmed
pubmed-article:8930374pubmed:authorpubmed-author:HsuehC MCMlld:pubmed
pubmed-article:8930374pubmed:authorpubmed-author:HuangH JHJlld:pubmed
pubmed-article:8930374pubmed:issnTypePrintlld:pubmed
pubmed-article:8930374pubmed:day21lld:pubmed
pubmed-article:8930374pubmed:volume737lld:pubmed
pubmed-article:8930374pubmed:ownerNLMlld:pubmed
pubmed-article:8930374pubmed:authorsCompleteYlld:pubmed
pubmed-article:8930374pubmed:pagination263-8lld:pubmed
pubmed-article:8930374pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:meshHeadingpubmed-meshheading:8930374-...lld:pubmed
pubmed-article:8930374pubmed:year1996lld:pubmed
pubmed-article:8930374pubmed:articleTitleActivation of mu-opioid receptors are required for the conditioned enhancement of NK cell activity.lld:pubmed
pubmed-article:8930374pubmed:affiliationDepartment of Education and Research, Taichung Veterans General Hospital, Taiwan.lld:pubmed
pubmed-article:8930374pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8930374pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:18386entrezgene:pubmedpubmed-article:8930374lld:entrezgene
entrez-gene:18390entrezgene:pubmedpubmed-article:8930374lld:entrezgene